Glazer Drug Company

Generic Drug Industry

Generic drugs are the equivalents of brand$-$name drugs, typically sold under their generic chemical names at prices below those of their brand$-$name equivalents. Generic drugs may be manufactured and marketed only if relevant patents on their brand$-$name equivalents have expired, been challenged or invalidated, or otherwise validly circumvented.

Future generic industry growth can be attributed to both a large number of branded drugs losing patent protection in the coming years and a strengthened desire by healthcare payers to increase generic drug utilization. The generic industry has seen rapid growth since the mid$-1980\text{'}$s$.$ Accompanying this growth has been a growing desire within the industry to challenge the legality of branded drug patents in court, often enabling patents to be overturned years ahead of schedule. Also attributing to the rapid generic growth is the appeal of Healthcare payers $($large employers and their benefit providers$)$ to

increasingly direct employees to buy more and more generics.

The Going Public Transaction

Glazer Drug Co$.$ one of the largest generic drug companies in the world, had annual sales of over $$3$ billion.. Its home office is in Mississauga, with its laboratories and sales outlets across Canada and in $30$ foreign countries, with the largest foreign operations in Great Britain and Australia. Its generic brand labels cover medication for heart disease, diabetes, acute infections, and many other ailments.

In the fall of $20xx,$ the company decided to go public. Its investment dealer was GMP Capital.

Glazer Drug Co$.\text{'}$s most recent $12-$month earnings were $$150$ million with one hundred million shares, providing an EPS figure of $$1\mathrm{.}50.$ After conducting a careful analysis of the generic drug industry, the investment dealer decided a $\frac{P}{E}$ of $25$ would be appropriate, giving a share value of

Accessibility: Good to go